Hitching a (Gene)Ride

How LogicBio could increase the safety of gene therapy

LogicBio Therapeutics Inc.’s GeneRide platform could reduce the oncogenic potential of gene therapies by co-opting the endogenous albumin promoter to express therapeutic transgenes.

GeneRide comprises a DNA cassette encoding a therapeutic transgene flanked by homology arms that target the albumin locus, which is highly expressed in the liver. The transgene is integrated at the albumin locus via homologous recombination, and transgene expression is

Read the full 636 word article

User Sign In